The present study was designed to evaluate whether etodolac, a cyclooxgenase-2 (COX-2)-specific inhibitor, could prevent chemically induced biliary carcinogenesis in bilioenterostomized hamsters. Syrian golden hamsters were subjected to choledochojejunostomy and then received subcutaneous injections of N-nitrosobis(2-oxopropyl)-amine (BOP) every 2 weeks at a dose of 10 mg/kg body wt. BOP administration was started 4 weeks after surgery, and continued for 18 weeks. The animals were simultaneously orally administered etodolac three times per week at a dose of 10 mg/kg body wt in 0.5% methylcellose solution (etodolac group). The control hamsters were administered methylcellose solution alone. The hamsters were killed 22 weeks after surgery, and the biliary carcinomas were evaluated histologically. The presence and degree of cholangitis and the cell kinetic status of the biliary epithelium were also evaluated with special reference to biliary carcinogenesis. Intrahepatic bile duct carcinomas developed in 15 of 17 (88%) hamsters in the control group, and in only six of 18 (33%) hamsters in the etodolac group (P 5 0.01). The incidence and number of developing biliary carcinomas were well correlated with the degree of cholangitis, and severe cholangitis was evident in the controls. The cell kinetic study demonstrated that the proliferating cell nuclear antigen-labeling index of the biliary epithelium was 9.67 and 5.14% in the control and etodolac groups, respectively (P 5 0.05). The mean levels of prostaglandin E 2 (PGE 2 ) products in the liver tissue were 14.14 AE 3.31 pg/ total protein (TP) mg in the control group, and 7.46 AE 2.34 pg/TP mg in the etodolac group (P 5 0.05). These findings indicated that etodolac reduced both the occurrence of severe cholangitis and the acceleration of biliary epithelial cell kinetics after bilioenterostomy, resulting in the prevention of BOP-induced biliary carcinogenesis in hamsters. In conclusion, COX-2-specific inhibitor (etodolac) may be a possible agent against not only reflux cholangitis, but also biliary carcinoma after bilioenterostomy.
Introduction
Bilioenterostomy is a common surgical technique that is widely used in the field of hepatobiliary pancreatic surgery. Reflux cholangitis (1--3) , biliary stones (3, 4) and liver abscess (2) are well-known complications after bilioenterostomy. Recently, clinical studies have revealed that biliary carcinomas occur as a delayed complication of bilioenterostomy for benign disease (5--7) . We have demonstrated that persistent reflux cholangitis after bilioenterostomy accelerated biliary carcinogenesis through an activation of biliary epithelial cell kinetics in hamsters (8, 9) .
Non-steroidal anti-inflammatory drugs (NSAIDs) are known to have anticarcinogenic effects on chemically induced or genetic mutational carcinogenesis (10--15) , and numerous epidemiological studies have indicated that NSAIDs reduced the incidence of colorectal cancer in humans (16--23) . On the other hand, cyclooxgenase-2 (COX-2), one of the major target molecules of NSAIDs has recently been demonstrated to be over-expressed in the inflamed biliary epithelium and biliary neoplasms in humans (24, 25) .
In this study, we investigated whether etodolac, a COX-2-specific inhibitor, could prevent biliary carcinogenesis in bilioenterostomized hamsters. We used Syrian golden hamsters because the anatomical structure of their pancreaticobiliary ductal system and the bile acid composition and pancreatic juice components in this species are similar to those of humans (26--28) , and concluded that etodolac is a possible agent for the prevention of biliary carcinogenesis in bilioenterostomized hamsters through the restraint of cholangitis. To the best of our knowledge, this is the first successful in vivo study on chemoprevention of biliary carcinogenesis by means of a COX-2-specific inhibitor.
Materials and methods

Animals
Seven-week-old female Syrian golden hamsters (SLC, Shizuoka, Japan) were housed, one per plastic cage, on sawdust bedding. They were kept at 24 AE 2 C and 50 AE 20% humidity with a 12-h light/12-h dark cycle, fed a CE-2 pelleted diet (Clea Japan, Tokyo, Japan), and provided drinking water ad libitum. The animals were checked daily and weighed weekly throughout the experiments. All experiments were conducted according to the Guidelines for Animal Experimentation of Nagasaki University.
Surgical techniques
Choledochojejunostomy using a Roux-en Y procedure was performed on all hamsters. The schemata of the completed surgical procedure of the choledochojejunostomy is illustrated in Figure 1 . Following anesthesia with sodium pentobarbital (50 mg/kg of body wt), an upper abdominal midline incision was made, and the distal end of the common bile duct was double-ligated with 6-0 nylon and divided. Following ligation of the cystic duct, the gallbladder was removed. The jejunum was double-ligated with 6-0 nylon and cut 7-cm distal to the pyloric ring of the stomach. About 4 cm of the anal side of the jejunum was used for the Roux-en Y anastomosis, and an intestinal anastomosis was made in a side-to-side manner with 7-0 nylon. A 20-G needle was inserted into the elevated jejunal wall~10 mm distal to the jejunal stump, and the tied common bile duct was then inserted into the hole that had been made by the Abbreviations: BOP, N-nitrosobis (2-oxopropyl) amine; COX-2, cyclooxgenase-2; NSAIDs, non-steroidal anti-inflammatory drugs; PGE 2 , prostaglandin E 2 ; PCNA-LI, proliferating cell nuclear antigen labeling index. needle. The common bile duct was then cut about half way towards the tied end for bile drainage, and taken back into the jejunum and fixed to the jejunal wall (8) .
Chemoprevention protocol
All hamsters that were operated on were given subcutaneous (s.c.) injections of a chemical carcinogen, N-nitrosobis (2-oxopropyl) amine (BOP) (Nakarai Tesque, Kyoto, Japan), every 2 weeks at a dose of 10 mg/kg body wt in 0.9% saline (29, 30) . BOP administration was started 4 weeks after surgery, and continued for 18 weeks (8, 30) . The animals were randomly divided into two groups according to the different regimens. Twenty hamsters were provided with an oral administration of etodolac (Nippon Shinyaku, Kyoto, Japan) three times per week at a dose of 10 mg/kg body wt (31) in 10 ml/kg body wt of 0.5% methylcellulose solution (Shin-Etsu Chemical, Tokyo, Japan) (32), starting 4 weeks after surgery, and continuing for 18 weeks (etodolac group). In the control group, 20 hamsters were provided with the same dose of methylcellulose solution alone. At postoperative week 22, all hamsters were killed.
Morphological and biochemical analyses
At autopsy, the maximum diameter of the extrahepatic bile duct was measured. Blood samples from the vena cava were collected in ice-chilled tubes containing heparin, centrifuged (3000 r.p.m) for 10 min, and then serum samples were collected in new ice-chilled tubes. The serum levels of total bilirubin (T-Bil), alkaline phosphatase (ALP), glutamic-oxaloacetic transaminase (GOT) and glutamic-pyruvic transaminase (GPT) were measured.
Histological studies
The liver, biliary system and pancreas were removed en bloc at autopsy. After fixation in 10% neutral formalin, the specimens were cut into five blocks so that four sections contained the liver and one section contained the hepatic duct, and embedded in paraffin. The histological sections were stained with hematoxylin and eosin (H&E), and then examined by a pathologist who was blinded to the treatment allocation of the sections. The number of histologically verified adenomas and carcinomas was counted. Carcinoma was diagnosed on the basis of disruption of epithelial cell polarity and evidence of an invasive event.
Inflammatory changes To evaluate the relationship between cholangitis and biliary carcinogenesis, the grade of cholangitis was scored in accordance with the infiltration of inflammatory cells and the fibrous change of Glison as follows: grade 0, no cholangitis; grade 1, mild invasion of inflammatory cells around the bile duct without fibrous change of Glison; grade 2, severe invasion of inflammatory cells around the bile duct and/or fibrous change of Glison; grade 3, abscess formation in the liver (8) .
Cell kinetic studies Proliferating cell nuclear antigen (PCNA) was used as a marker of biliary epithelial cell kinetics. Tissue sections were cut at 4-mm, mounted on glass slides coated with 5-aminoprophyltriethoxy saline and dewaxed in xylene. The sections were treated with microwave heating for 5 min in phosphate-buffered saline at 500 W. After the blocking of endogenous peroxidase, the sections were incubated with mouse monoclonal antibodies against PCNA (clone-PC 10; DAKO, Kyoto, Japan) at a dilution of 1:100. The cell nuclei were counterstained with hematoxylin. The proportion of labeled nuclei (labeling index; LI) was determined by counting the labeled nuclei in 41000 nonneoplastic epithelial cells of the intrahepatic bile ducts (33) .
Activity of cyclooxgenase
Prostagrandin E 2 (PGE 2 ) production in the liver tissue was used as a marker of inflammation and COXs activity. At autopsy, the right lateral lobe of the liver was removed, immediately frozen in liquid nitrogen, and stored at À80 C in a sterile 1.5 ml Eppendorf tube until analysis. The frozen tissue was homogenized in saline containing 10 mg/l indomethacin, and ethanol was added to achieve the final proportion of 20%. After centrifugation, the supernatant was removed and agitated in the octadecylsilyl silica (ODS) suspension to adsorb PGE 2 . Protein and lipids were eliminated from the ODS carrier by washing with ethanol, hydrochloric acid and petroleum ether in turn. Then, PGE 2 was eluted from the ODS carrier by adding acetic ether, and measured by a radioimmunoassay (RIA) technique using a prostaglandin E 2 [ In order to evaluate normal levels of PGE 2 production in the liver tissue and PCNA-LI of the biliary epithelium, 12 29-week-old hamsters that had received no treatment were also investigated.
Adverse effects of etodolac on vital state
The side effects of etodolac, such as gastrointestinal mucosal injury, liver and renal dysfunction, and eosinophilic pneumonia, may have adverse effects on the vital state. Accordingly, the animals were checked daily and weighed weekly throughout the experiments.
Statistical analyses
The incidence of tumor development and grade of cholangitis were analyzed using the x 2 exact test. The Mann--Whitney test was also used for statistical analyses of the diameter of the extrahepatic bile duct, number of tumors per animal, laboratory data on serum, and PCNA-LI and PGE 2 production. Differences of P 5 0.05 were considered statistically significant. Table I summarizes the morphological and biochemical changes in the hepatobiliary system of the hamsters. The total number of hamsters examined was 17 and 18 in the control and etodolac groups, respectively. Three hamsters in the control group and two in the etodolac group died of liver abscess and/or obstructive jaundice before death. The average diameter of the extrahepatic bile duct was 2.8 AE 1.9 mm in the control and 1.9 AE 1.3 mm in the etodolac group, and there was no significant difference between the two groups. However, the serum levels of T.Bil, GOT and ALP were significantly higher in the control group than in the etodolac group (P 5 0.05).
Results
Morphological and biochemical changes
Occurrence of biliary tumors
Biliary adenomas and carcinomas were observed in the hamsters in both groups (Table II ). The occurrence rates of adenoma were 88 and 61% of the hamsters in the control and etodolac groups, respectively, and there was no significant difference in the incidence of adenoma between the two groups. However, numerous biliary adenomas occurred in the control group, and the average number of adenomas per animal was much higher in the control group than in the etodolac group (P 5 0.01).
In the control group, intrahepatic bile duct carcinoma developed in 15 of 17 (88%) hamsters, and the average number of carcinomas per animal was 11.4. In the etodolac group, only six of 18 (33%) hamsters developed intrahepatic bile duct carcinoma, and the average number of carcinomas per animal was 1.8. Both the incidence of carcinoma and the average number of carcinomas per animal were significantly lower in the etodolac group than in the control group (P 5 0.01).
Cholangitis, biliary epithelial cell kinetics, PGE 2 production and biliary carcinogenesis Cholangitis was recognized in all hamsters in the control group and 89% of the hamsters in the etodolac group (Table III) . However, severe cholangitis was frequently observed in the control hamsters, and the average cholangitis score was significantly higher in the control group (P 5 0.05).
PCNA-LI of the biliary epithelium was 9.67 AE 5.90% in the control group, and this value was significantly higher than that of the etodolac group (P 5 0.05). In addition, the PCNA-LI of the biliary epithelium in hamsters that received no treatment was 2.4 AE 1.5%.
The mean level of PGE 2 products in the liver tissue was 14.14 AE 3.31 pg/TP mg in the control group, and this value was significantly higher than the value of 7.46 AE 2.34 pg/total protein (TP) mg for the etodolac group (P 5 0.05). In hamsters that received no treatment, it was 1.5 AE 0.1 pg/TP mg, and this value was significantly different from the value of both the control and etodolac groups (P 5 0.05). Figure 2 shows the correlation between the cholangitis score and biliary carcinogenesis. Concerning the degree of cholangitis, highly scored cholangitis of grade 2 or 3 was observed in 59% of the hamsters in the control group, and 22% of the hamsters in the etodolac group. In the control group, biliary carcinomas were frequently observed in each grade of cholangitis. In the etodolac group, in contrast, the incidence of biliary carcinoma decreased along with the degree of cholangitis, and carcinomas were observed in only two of the 14 hamsters with cholangitis of grade 0 or 1. Figure 3 shows the transition curves of the body weight of hamsters during the experiment. Until the 15th week of the study, the average body weight of the hamsters in both groups increased in a similar fashion. Thereafter, the body weight of the hamsters in the etodolac group increased continuously, while that in the control group gradually decreased.
Transition of body weight
Discussion
Intrahepatic and extrahepatic biliary carcinomas have a dismal outcome even if the tumor is resected, and tolerate with traditional cytotoxic chemo-and radio-therapeutic approaches. Mean AE SD. b Significantly different from control group (P 5 0.01).
Fig. 2.
Correlation between cholangitis score and biliary carcinogenesis in hamsters after bilioenterostomy. Black circle, hamster with carcinoma; clear circle, hamster without carcinoma. 
Chemopreventation of biliary carcinogenesis
Cancer chemoprevention is, thus, now expected to be a new approach in the management of biliary carcinoma. Recently, numerous studies have proved that NSAIDs reduce the incidence of several kinds of cancer (34--36) . We obtained evidence that persistent cholangitis after bilioenterostomy accelerated the development of biliary carcinoma in hamsters, and that more severe cholangitis was associated with a higher occurrence of biliary carcinoma through an increase in the proliferative activity of the biliary epithelium (8, 9) . Therefore, we expected that NSAIDs could reduce biliary carcinogenesis by inhibiting biliary inflammation. The present study clearly demonstrated a preventative effect of etodolac on BOP-induced biliary carcinogenesis in hamsters undergoing bilioenterostomy. Although etodolac failed to inhibit the occurrence of reflux cholangitis, a reduction in the degree of cholangitis was apparent in the etodolac group. Moreover, etodolac down-regulated the cell kinetic activity of the biliary epithelium. These findings indicated that reflux cholangitis was inevitably induced after choledochojejunostomy, but the aggravation of cholangitis was attenuated by etodolac. The inhibitory effects of etodolac on inflammation and inflammation-activated biliary epithelial cell kinetics may participate in the tumor-preventing mechanisms in our hamster model.
It is well known that COXs mediate the rate-limiting step of prostaglandin, including PGE 2 , biosynthesis in the arachidonic acid cascade, and PGE 2 is considered to be a reliable biomarker of COXs activity (38) . On the other hand, PGE 2 is well known to be up-regurated in inflammatory sites through upregulated COXs activity. In addition, recent in vitro studies have demonstrated that COX-2 and COX-2-mediated prostanoids, including PGE 2 , are strongly related to cancer development and progression through their anti-apoptotic effects (38), enhancement of angiogenesis or suppression of cell-to-cell adhesive activity (39--41) . In the present study, PGE 2 products in the liver tissue were significantly decreased in the etodolac group. Although the tissue of interest is the epithelium of the intrahepatic bile duct, it is probable that the changes seen in the liver will be similar to those in the bile duct epithelium. Considering our findings and the evidence reported above, the inhibition of COXs activity, especially COX-2, is considered to be another possible mechanism of the chemopreventive effect of etodolac on biliary carcinogenesis in bilioenterostomized hamsters.
The toxicity and efficacy of NSAIDs are mediated through the inhibition of COX-mediated prostaglandin synthesis (42) . Due to the non-selective inhibitory effects of conventional NSAIDs on COX-1 and COX-2, which results in many untoward side effects, including gastrointestinal bleeding, their clinical use is limited. However, etodolac mainly inhibits COX-2, and its adverse effects on the gastrointestinal tract can occur less frequently (43) . In our study, the body weight of hamsters in the etodolac group was well maintained throughout the experiment, in contrast to the hamsters in the control group. These facts suggested that etodolac had no critical adverse effects. Thus, long-term administration of etodolac might be feasible and also convenient for cancer prevention.
In conclusion, etodolac inhibited BOP-induced biliary carcinogenesis in hamsters undergoing choledochojejunostomy. Suppression of the proliferative activity of the biliary epithelial cells and reduction of PGE 2 products in the liver in association with the attenuation of persistent cholangitis by etodolac were considered possible mechanisms of cancer prevention in this hamster model. Information that supports the benefits of etodolac in the management of reflux cholangitis was also obtained in this study. Clinical trials will be necessary to assess the utility of specific COX-2 inhibitors, not only in the prevention of biliary carcinogenesis, but also in the treatment of reflux cholangitis in patients undergoing bilioenterostomy. N.Tsuneoka et al.
